H.C. Wainwright analyst Edward White raised the firm’s price target on InflaRx to $10 from $6 and keeps a Buy rating on the shares after the FDA granted an EUA for Gohibic in COVID-19 critically ill patients. The firm, which notes that pricing of the drug is "expected to be in the five-digit range," anticipates a launch in Q3 of 2023 for Gohibic for COVID-19 with sales of $10M this year and $91M in 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IFRX:
- InflaRx upgraded to Outperform from Market Perform at LifeSci Capital
- InflaRx (NASDAQ:IFRX) Stock Spikes: Is There Further Upside?
- InflaRx up 47% after receiving EUA for Gohibic use in COVID-19 treatment
- InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
- InflaRx announces Gohibic receives FDA Emergency Use Authorization